11 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 11, Recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
Follow Phentermine: new trials by email Literature Review of Phentermine trials Research Report on Phentermine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation Phentermine Pill, Orforglipron - Obesity | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 60 | 2026-11-01 | 2026-07-27 |
| Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect) - Liver Cirrhoses, Portal Hypertension Related to Cirrhosis | Phase 4 | Recruiting | The Cleveland Clinic | 70 | 2025-12-17 | 2026-10-22 |
| Treating Toddler Obesity by Treating the Parent/Caregiver Obesity With Weight Loss Medications Lomaira 8Mg Tablet - Weight Loss, Obesity, Childhood | Phase 4 | Withdrawn | Loma Linda University | 2025-12-01 | 2025-11-20 | |
| Intermittent Phentermine for Obesity and Body Composition Phentermine 15 MG, Phentermine 30 mg, Phentermine 37.5 Mg - Obesity & Overweight | Phase 4 | Completed | OSCAR MANUEL TORRES FALCON | 600 | 2024-03-01 | 2026-10-13 |
| Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery Topiramate, Phentermine, Placebo - Obesity | Phase 4 | Recruiting | University of California, Irvine | 120 | 2023-08-29 | 2026-10-19 |
| Long-term Effectiveness of the Antiobesity Medication Phentermine Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG - Obesity, Obesity; Drug | Phase 4 | Completed | Wake Forest University Health Sciences | 870 | 2022-06-30 | 2026-11-05 |
| A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects VI-0521, Phentermine, Placebo - Blood Pressure | Phase 4 | Completed | VIVUS LLC | 565 | 2022-01-25 | 2024-07-17 |
| Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity Phentermine 37.5 Mg, Dietary program, Exercise program - Obesity | Phase 4 | Completed | The Cleveland Clinic | 70 | 2021-01-01 | 2022-12-07 |
| EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule - Type 2 Diabetes, Obesity | Phase 4 | Terminated | The Cleveland Clinic | 74 | 2020-09-01 | 2024-09-19 |
| Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment Behavioral Treatment, Placebo, Phentermine 15 MG - Obesity | Phase 4 | Completed | University of Pennsylvania | 147 | 2019-07-15 | 2025-03-11 |
| Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery Phentermine, Placebo - Obesity, Morbid Obesity | Phase 4 | Completed | Hospital Juarez de Mexico | 92 | 2018-03-01 | 2020-07-29 |
| Lifestyle Modification and Liraglutide CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet - Obesity | Phase 4 | Completed | University of Pennsylvania | 150 | 2016-09-01 | 2019-05-07 |
| Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects Qsymia, Placebo - Obesity | Phase 4 | Completed | VIVUS LLC | 51 | 2014-08-01 | 2017-11-07 |
| A Toolbox Approach to Obesity Treatment in Primary Care Commercial weight loss program, Colorado Weigh, Meal replacements - Obesity | Phase 4 | Completed | Denver Health and Hospital Authority | 4730 | 2014-01-01 | 2017-08-18 |
| A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl - Chronic Weight Management | Phase 4 | Completed | Eisai Inc. | 344 | 2013-10-30 | 2019-09-30 |
| Studying the Effects of Phentermine on Eating Behavior Phentermine, placebo - Obesity | Phase 4 | Completed | New York State Psychiatric Institute | 13 | 2012-07-01 | 2017-07-31 |
Obesity (15) · Weight Loss (5) · Overweight (3) · Obesity, Morbid (2) · Anorexia (1) · Appetitive Behavior (1) · Body Weight (1) · Body Weight Changes (1) · Diabetes Mellitus, Type 2 (1) · Non-alcoholic Fatty Liver Disease (1) · Pediatric Obesity (1) · Signs and Symptoms (1)
The Cleveland Clinic (3) · University of Pennsylvania (2) · VIVUS LLC (2) · Denver Health and Hospital Authority (1) · Eisai Inc. (1) · Hospital Juarez de Mexico (1) · Loma Linda University (1) · Massachusetts General Hospital (1) · New York State Psychiatric Institute (1) · OSCAR MANUEL TORRES FALCON (1) · University of California, Irvine (1) · Wake Forest University Health Sciences (1)
United States (14) · Mexico (2)
Ali Aminian, MD (1) · Bartolome Burguera (1) · Chris Galloway, MD (1) · Daniel H Bessesen, MD (1) · Jamy D Ard, MD (1) · Jena S Tronieri, PhD (1) · Kishore M Gadde, MD (1) · Kristina H Lewis, MD (1) · Laurel Mayer, MD (1) · Marcio Griebeler, MD (1) · Nicholas M Pajewski, PhD (1) · Thomas A Wadden, Ph.D. (1) · Warren C Peters, MD (1)
PMID 21593294, PMID 25590212, PMID 28440045, PMID 29363287, PMID 30257072, PMID 30421856, PMID 30902750, PMID 30926955, PMID 31241358, PMID 31485965, PMID 32313674, PMID 36156456, PMID 38304225, PMID 40055520
R01DK129936 (1), UG3HL155801 (1)